How CagriSema compares to approved GLP-1 drugs CagriSema sits in tirzepatides efficacy range
Source, dose, formulation, quality, prescribing oversight, and regulatory status matter
It is a significant acknowledgment that obesity should be recognized as a chronic disease, as opposed to a lifestyle choice. How much does Wegovy cost with Aetna
Fatigue: Ensuring adequate hydration and gradual adjustments to the dosage often help combat feelings of tiredness
Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%
Plaha NS, Awasthi S, Sharma A, Kaushik N
